TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Ainos ( (AIMD) ) is now available.
On November 7, 2025, Ainos held its annual meeting of stockholders in Taiwan, where seven directors were elected, and key proposals were ratified, including the appointment of YCM CPA INC. as the independent auditor and the reservation of shares for special stock awards. Ainos also reported its third-quarter financial results, highlighting the acceleration of its AI Nose commercialization through strategic partnerships and product launches. The company secured new patents, expanded its industrial collaborations, and showcased its technology at major exhibitions, reinforcing its market position in the growing electronic-nose market projected to reach $130 billion by 2034. Ainos’ focus on AI-driven scent digitization and its expanding SmellTech-as-a-Service model are positioning it for significant growth, particularly in the Asia Pacific region.
The most recent analyst rating on (AIMD) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Ainos stock, see the AIMD Stock Forecast page.
Spark’s Take on AIMD Stock
According to Spark, TipRanks’ AI Analyst, AIMD is a Neutral.
Ainos’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, while valuation metrics reflect ongoing financial challenges. The absence of earnings call data and corporate events leaves these areas unaddressed.
To see Spark’s full report on AIMD stock, click here.
More about Ainos
Ainos, Inc. is a dual-platform AI and biotech company pioneering SmellTech and oral interferon therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases.
Average Trading Volume: 73,661
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.65M
Find detailed analytics on AIMD stock on TipRanks’ Stock Analysis page.